Oncotarget

Research Papers:

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity

Soyoko Morimoto, Fumihiro Fujiki _, Kenta Kondo, Hiroko Nakajima, Yoshiki Kobayashi, Miki Inatome, Nao Aoyama, Yuya Nishida, Akihiro Tsuboi, Yoshihiro Oka, Sumiyuki Nishida, Jun Nakata, Naoki Hosen, Yusuke Oji and Haruo Sugiyama

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:34132-34141. https://doi.org/10.18632/oncotarget.26139

Metrics: PDF 1478 views  |   HTML 2142 views  |   ?  


Abstract

Soyoko Morimoto1, Fumihiro Fujiki2, Kenta Kondo3, Hiroko Nakajima2, Yoshiki Kobayashi3, Miki Inatome3, Nao Aoyama3, Yuya Nishida3, Akihiro Tsuboi1, Yoshihiro Oka4,5,6, Sumiyuki Nishida5, Jun Nakata1, Naoki Hosen4, Yusuke Oji3 and Haruo Sugiyama2

1Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan

2Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan

3Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan

4Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan

5Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan

6Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, Osaka, Japan

Correspondence to:

Fumihiro Fujiki, email: fu-fuji@sahs.med.osaka-u.ac.jp

Keywords: WT1; TCR; TCR functional avidity; TCR-engineered T-cell therapy

Received: May 22, 2018     Accepted: September 10, 2018     Published: September 25, 2018

ABSTRACT

Adoptive T-cell therapy with T cell receptor (TCR) -engineered T cells is an attractive strategy for cancer treatment and the success in this therapy is dependent on the functional avidity of the transduced TCRs against targeted tumor antigens. Therefore, the establishment of the methodology of the efficient and precise evaluation of TCR functional avidity has been awaited. Here, we show a novel platform cell line, named 2D3, which enables the functional avidity of transduced TCRs to be evaluated efficiently and precisely. In the 2D3, the precise TCR functional avidity of transduced TCRs is easily evaluable by the expression of green fluorescent protein (GFP) reporter gene driven by nuclear factor of activated T cells (NFAT) activation via TCR signaling. Four different TCRs of HLA-A*24:02-restricted Wilms’ tumor gene 1 (WT1)-specific CD8+ cytotoxic T lymphocytes (CTLs) were transduced into 2D3 cells and the functional avidities of these four TCRs were evaluated. The evaluated functional avidity of these TCRs positively correlated with cell proliferation, cytokine production, and WT1-specific cytotoxicity of the TCR-transduced CD8+ T cells in response to WT1 antigen. These results showed that 2D3 cell line was a novel and stable tool useful for the efficient and precise evaluation of the functional avidity of isolated and transduced TCRs in developing TCR-based immunotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26139